Twist Bioscience stock

TWST · NASDAQ · USD

Compare Twist Bioscience
$112.00Change from previous close: +6.63%Absolute change: +$6.96

Close · November 17, 2026

Price history

+305.93% over the period

1 year: from $26.46 (November 17, 2025) to $107.41 (November 17, 2026), +305.93%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$107.41
October 30, 2026$152.78
September 30, 2026$193.24
August 31, 2026$139.00
July 31, 2026$91.55
June 30, 2026$102.88
May 29, 2026$66.87
April 30, 2026$58.45
March 31, 2026$47.52
February 27, 2026$46.92
January 30, 2026$41.07
December 31, 2025$31.72
November 28, 2025$32.01
November 17, 2025$26.46

At a glance

  • The company

    Manufactures synthetic DNA-based products for therapeutics, diagnostics, chemicals, food, data storage and research applications

  • Latest results

    Quarter to September 30, 2026 · EPS -$0.32 (estimate -$0.38)

TickerLandia's take on Twist Bioscience

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$24.41
52-wk high$219.71

−49.02% from the 52-week high

Analysts · 13 analysts

Average target$135.17+20.68% vs. price

Buy 9 · Hold 3 · Sell 1 · Buy

TickerLandia Fingerprint: Twist Bioscience

Compared with similar companies: very high risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Twist Bioscience is in line with similar companies

Twist Bioscience's Price/book: 15.7, in line with the median of a group of 9 similar companies (15.7).

Compared with 11 similar companies

Twist Bioscience's metrics compared with similar companies
MetricTwist BiosciencePosition in the groupBand
Operating margin-28.8%Low
ROE-19.1%Low
Debt/equity0.12Middle
Price/book15.7Middle
Net margin-28.3%Low

Grey band: the middle half of the group; tick: the median; dot: Twist Bioscience. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$118.38M

Latest quarter · Q2 2026

Net income

-$35.05M

Latest quarter · Q2 2026

Quarterly net margin

-29.6%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$7.4B
EPS
-$2.23
Volume
2.05M
Daily trading
€302.74M
Dividend yield
0.00%

How Twist Bioscience is changing

All results
  • Revenue grew 33.1% a year on average over the last 5 years

  • Operating margin rose from −122.3% to −36.2%

  • Shares outstanding up 52.6% in 5 years

Returns

Twist Bioscience returns

$1,000 invested in Twist Bioscience 5 years ago, on November 17, 2021, would be worth $926 today: −7.40% in total, −1.53% per year. This is the price return only: dividends are excluded.

PeriodTwist BioscienceS&P 500$1,000 becomes
1 month−23.15%−3.17%$768
6 months+127.78%+0.11%$2,278
Year to date+238.62%+8.34%$3,386
1 year+305.93%+11.15%$4,059
3 years+347.36%+64.30%$4,474
5 years−7.40%+58.18%$926

Over the last 6 months it has done better than 99% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Twist Bioscience: technical analysis

Twist Bioscience shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 46.1% below its all-time closing high ($207.97, January 20, 2021).

Trend
No clear trend
RSI (14 sessions)
40
Between 30 and 70
vs 200-session average
+19.30%

Support and resistance

Price areas where Twist Bioscience has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$117.74+5.12%2 touches, last on September 10, 2026
  2. Last price$112.00
  3. Support$83.42−25.52%4 touches, last on August 3, 2026
  4. Support$66.24−40.85%2 touches, last on June 9, 2026
  5. Support$39.07−65.12%9 touches, last on March 30, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
2.96
Volatility (60 sessions, annualised)
108.2%
Largest fall in the last year
−48.76%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Twist Bioscience: seasonality

Average monthly price change over 8 years

+7.8%Jan−3.4%Feb−6.0%Mar−3.7%Apr+8.7%May+23.8%Jun+8.7%Jul−0.7%Aug+1.7%Sep−4.0%Oct+21.3%Nov+2.1%Dec

Over the last 8 years, the strongest month for Twist Bioscience has been June: +23.84% on average, positive in 8 years out of 8. The weakest has been March: −6.02% on average, positive in 3 years out of 8. November, the current month, has been positive in 5 years out of 8 (+21.29% on average).

Show chart data
MonthAverageMedianPositive years
January+7.78%+14.58%6 of 8
February−3.42%−5.87%3 of 8
March−6.02%−5.07%3 of 8
April−3.73%−0.16%4 of 8
May+8.69%+15.21%6 of 8
June+23.84%+21.77%8 of 8
July+8.73%+14.74%5 of 8
August−0.68%−8.97%2 of 8
September+1.65%−0.59%4 of 8
October−4.01%−3.55%3 of 8
November+21.29%+10.95%5 of 8
December+2.10%−8.69%2 of 8

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Twist Bioscience and its competitors

Biotech and pharmaceutical developers, academic laboratories, and food, agriculture and materials companies are the customers of Twist Bioscience Corporation, which makes synthetic DNA-based products for them. Its main offer is synthetic genes and gene fragments for product development in therapeutics, diagnostics and data storage, complemented by oligo pools for CRISPR gene editing and DNA computing, and by antibody libraries. It also sells NGS library preparation kits, exome kits and custom panels, methylation detection kits for cancer research, and synthetic viral controls, including SARS-CoV-2 reference sequences.

Headquarters
South San Francisco, United States
Employees
979
Founded
2013
Chief executive
Emily Leproust
Twist Bioscience and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Twist BioscienceTWST$7.4B-28.8%—+127.78%
ImmunityBioIBRX$6.4B-150.2%—−21.46%
Corcept TherapeuticsCORT$9.36B0.8%190.2+24.30%
Madrigal PharmaceuticalsMDGL$9.93B-10.7%—−19.42%
BioMarin PharmaceuticalBMRN$11.09B16.3%146.8+12.93%
Summit TherapeuticsSMMT$11.32B0.0%—−36.75%

Same industry or related industries, similar size. Compare Twist Bioscience with its competitors · Full profile